Literature DB >> 32684858

Factors influencing the use of adaptive radiation therapy in vulvar carcinoma.

Fawzi Abuhijla1, Samer Salah2, Maysa Al-Hussaini3, Issa Mohamed1, Imad Jaradat1, Abdulmajeed Dayyat1, Hanan Almasri1, Alaa Allozi1, Ayah Arjan1, Abdelatif Almousa1, Ramiz Abu-Hijlih1.   

Abstract

AIM: We aim to evaluate the variables affecting the frequency of adaptive radiotherapy (ART) in vulvar cancer.
BACKGROUND: ART may be needed throughout a definitive RT course for vulvar carcinoma due to changes in patient's anatomy and tumor response.
MATERIALS AND METHODS: Charts of patients charts who had been treated with definitive concurrent chemo-radiotherapy for vulvar carcinoma, between January 2015 and December 2019 were inquired. Radiation therapy was delivered using intensity modulated radiotherapy (IMRT) with daily image-guided radiotherapy (IGRT). ART was defined as re-simulation and re-planning based on deformation in the irradiated volume by more than 1 cm. Univariate analysis was conducted to study the impact of patient's demographics as well as tumor characteristics on the frequency of ART.
RESULTS: 22 patients were eligible for analysis. Median age at diagnosis was 55 years (range 43-82). Radiotherapy dose was 60-66 Gy over 30-35 fractions (fx). Median primary tumor volume was 30cc (9-140). Median Body Mass Index (BMI) was 32 (range 21-40). Thirteen out of 22 patients (59%) required ART, with median timing at 25 fx (19-31). On univariate analysis, larger primary tumor volume (> = 30cc) was associated significantly with increased frequency of ART (p value = 0.0005). There was no significant impact of ART on the frequency with respect to patient's age, BMI, tumor stage, grade and location.
CONCLUSION: Changes in radiation target volume are common among vulvar carcinoma patients who are treated with definitive radiotherapy, especially large primary tumors. This review highlights the importance of ART for patients with vulvar carcinoma treated with definitive radiotherapy.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adaptive; Factors; Radiotherapy; Vulva

Year:  2020        PMID: 32684858      PMCID: PMC7358621          DOI: 10.1016/j.rpor.2020.06.005

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  24 in total

1.  A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study.

Authors:  David H Moore; Shamshad Ali; Wui-Jin Koh; Helen Michael; Mack N Barnes; Carolyn K McCourt; Howard D Homesley; Joan L Walker
Journal:  Gynecol Oncol       Date:  2011-11-09       Impact factor: 5.482

2.  Vulvar cancer in high-income countries: Increasing burden of disease.

Authors:  Yoon-Jung Kang; Megan Smith; Ellen Barlow; Kate Coffey; Neville Hacker; Karen Canfell
Journal:  Int J Cancer       Date:  2017-08-30       Impact factor: 7.396

Review 3.  Uncertainties in volume delineation in radiation oncology: A systematic review and recommendations for future studies.

Authors:  Shalini K Vinod; Michael G Jameson; Myo Min; Lois C Holloway
Journal:  Radiother Oncol       Date:  2016-10-08       Impact factor: 6.280

4.  The promise of adaptive radiotherapy for pelvic tumors: "too high cost for too little result" or "a low cost for a significant result"?

Authors:  Claudio Fiorino; Cesare Cozzarini; Paolo Passoni
Journal:  Acta Oncol       Date:  2016-07-01       Impact factor: 4.089

5.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

6.  Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis.

Authors:  Beant S Gill; Mark E Bernard; Jeff F Lin; Goundappa K Balasubramani; Malolan S Rajagopalan; Paniti Sukumvanich; Thomas C Krivak; Alexander B Olawaiye; Joseph L Kelley; Sushil Beriwal
Journal:  Gynecol Oncol       Date:  2015-04-11       Impact factor: 5.482

Review 7.  Multimodality imaging of vulvar cancer: staging, therapeutic response, and complications.

Authors:  Chitra Viswanathan; Kimberly Kirschner; Mylene Truong; Aparna Balachandran; Catherine Devine; Priya Bhosale
Journal:  AJR Am J Roentgenol       Date:  2013-06       Impact factor: 3.959

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes.

Authors:  Yuan James Rao; Anupama Chundury; Julie K Schwarz; Comron Hassanzadeh; Todd DeWees; Daniel Mullen; Matthew A Powell; David G Mutch; Perry W Grigsby
Journal:  Adv Radiat Oncol       Date:  2017-02-28

Review 10.  Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy.

Authors:  C McGough; C Baldwin; G Frost; H J N Andreyev
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.